Carcinoma, Hepatocellular

Showing NaN - NaN of 19

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)

Recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +62 more
Feb 1, 2023

Carcinoma, Hepatocellular Trial in Worldwide (drug, biological, procedure)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Tucson, Arizona
  • +206 more
Jan 31, 2023

Carcinoma, Hepatocellular Trial in Spain (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Elche, Alicante, Spain
  • +26 more
Dec 5, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +138 more
Aug 22, 2022

Tolerability of Lenvatinib in Advanced or Unresectable

Recruiting
  • Carcinoma, Hepatocellular
  • Clovis, California
  • +48 more
Aug 12, 2022

Carcinoma, Hepatocellular, Colorectal Tumors, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Pembrolizumab, Belzutifan,

Recruiting
  • Carcinoma, Hepatocellular
  • +5 more
  • Duarte, California
  • +39 more
Jul 29, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Phoenix, Arizona
  • +118 more
Jun 14, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care)

Completed
  • Carcinoma, Hepatocellular
  • Doxorubicin 20 mg/m2
  • +2 more
  • Canton, Ohio
  • +69 more
May 28, 2021

Carcinoma, Hepatocellular Trial in Worldwide (CC-122, Nivolumab)

Completed
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +13 more
Apr 16, 2021

Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))

Completed
  • Carcinoma, Hepatocellular
  • Refametinib (BAY86-9766)
  • Sorafenib (BAY43-9006)
  • Louisville, Kentucky
  • +78 more
Apr 6, 2021

Carcinoma, Hepatocellular Trial in Worldwide (LY2157299, Sorafenib, Ramucirumab)

Completed
  • Carcinoma, Hepatocellular
  • Fayetteville, Arkansas
  • +39 more
Dec 21, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Regorafenib (Stivarga, BAY73-4506), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Regorafenib (Stivarga, BAY73-4506)
  • Placebo
  • Los Angeles, California
  • +146 more
Aug 11, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Placebo, GC33)

Completed
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +56 more
Apr 1, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006)
  • +2 more
  • San Francisco, California
  • +126 more
May 16, 2019

Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Nexavar (Sorafenib, BAY43-9006)
  • Placebo
  • Birmingham, Alabama
  • +198 more
Jul 11, 2018

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006)
  • Placebo
  • La Jolla, California
  • +106 more
Jul 18, 2017

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006)
  • Placebo
  • Phoenix, Arizona
  • +177 more
Oct 24, 2014

Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular Trial in Worldwide

Terminated
  • Hepatocellular Carcinoma Non-resectable
  • +12 more
  • Beverly Hills, California
  • +162 more
Sep 7, 2012